|C10BX - Hmg Coa Reductase Inhibitors, Other Combinations||ATC-DDD Version 2016. Source: WHO|
|C - Cardiovascular System|
|C10 - Lipid Modifying Agents|
The DDDs are based on the treatment of hypercholesterolemia.
|C10B - Lipid Modifying Agents, Combinations|
Fixed combinations of blood glucose-lowering drugs and lipid modifying agents are classified in A10B.
For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively.
|C10BX - Hmg Coa Reductase Inhibitors, Other Combinations|
Combinations with e.g. ACE inhibitors, angiotensin II antagonists, calcium channel blockers or diuretics are classified in C10BX.
The DDD for the fixed combination of rosuvastatin and valsartan is 1 UD (1 tablet), regardless of strength.